Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
6.810
-0.100 (-1.45%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
21
22
23
24
25
26
27
28
Next >
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
The Year In Review For Psychedelic Drug Stocks: 2021
December 21, 2021
2021 was two different
Via
Talk Markets
Why Jim Cramer Likes MGM Growth Properties
December 21, 2021
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Enterprise Products Partners L.P. (NYSE:
Via
Benzinga
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
Psychedelics Company COMPASS Pathways To Join NASDAQ Biotechnology Index
December 17, 2021
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:
Via
Benzinga
North American Psychedelic Drugs Market Expected To Reach A Value Of $3.184 Billion In 2026
December 14, 2021
Palm Beach, FL –December 14, 2021 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially, and the development of novel medications has not kept...
Via
FinancialNewsMedia
Compass Pathways (NASDAQ: CMPS) Announces Promising Data from Psilocybin Therapy Trial
December 13, 2021
Via
Investor Brand Network
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
December 13, 2021
Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ:
Via
Benzinga
Cannabis & Psychedelic Compound-Based Drug Stocks Continue To Decline
December 12, 2021
The six marijuana-based clinical-stage stocks are down 31.1% since the end of June; the 9 psychedelic compound-based clinical-stage stocks with market caps under $1B are down 36.3% in that same...
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
Atai Life Sciences (NASDAQ: ATAI) Increases Stake in Psychedelic Start-Up Compass Pathways
December 07, 2021
Via
Investor Brand Network
Cannabis Movers & Shakers: Coda Signature, Greater Cannabis Co., BioHarvest Sciences, Compass Pathways
December 06, 2021
Coda Signature Taps Teddy C. Scott As Board Member Producer of cannabis-infused edibles and wellness products Coda Signature
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers
December 03, 2021
In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “
Via
Benzinga
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
December 01, 2021
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher...
Via
Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ...
Via
Benzinga
Were Compass Pathways' Clinical Trial Results Really That Bad?
November 28, 2021
The biotech was priced for perfection; its data wasn't.
Via
The Motley Fool
Exposures
Product Safety
10 Biggest Price Target Changes For Monday
November 22, 2021
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...
Via
Benzinga
Better Buy: Compass Pathways vs. Jazz Pharmaceuticals
November 21, 2021
Both of these biotech stocks are innovators, but one is more likely to hit it out of the park.
Via
The Motley Fool
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
How One Company Says It Aims To Demonstrate the Superiority of Psilocin Over Psilocybin in Treating Mental Health Conditions
November 16, 2021
Image by Mathew Schwartz from Unsplash The following post was written and/or pu...
Via
Benzinga
Is Now the Right Time to Buy Compass Pathways?
November 13, 2021
Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted.
Via
The Motley Fool
Why Compass Pathways Stock Slumped This Week
November 12, 2021
Positive trial results weren't enough to keep the company's shares from sinking this week.
Via
The Motley Fool
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
November 17, 2021
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion...
Via
FinancialNewsMedia
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
November 11, 2021
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
Via
InvestorPlace
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
November 11, 2021
Investors might want to give this psychedelic stock another look.
Via
The Motley Fool
75 Biggest Movers From Yesterday
November 10, 2021
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...
Via
Benzinga
COMPASS Pathways plc (CMPS) Q3 2021 Earnings Call Transcript
November 09, 2021
CMPS earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Compass Pathways Shares Are Slumping More Than 22% Tuesday
November 09, 2021
The stock dropped more than $13 on Tuesday.
Via
The Motley Fool
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
November 09, 2021
Shares plunged, despite a psilocybin-based drug reducing depression in a trial.
Via
Investor's Business Daily
< Previous
1
2
...
21
22
23
24
25
26
27
28
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.